GDTC stock Statistics — CytoMed Therapeutics Ltd filings, insiders & smart money

Beta: Sign in
Shares outstandingAs of 2025-12-31 · filed common shares: 11.82M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 4.48%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 0.05%
Short ratioDays to cover, as published by FINRA: 1.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 41.30%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 48.90%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Sign in

Avg volume (3 months)

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -51.33%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -44.10%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, FY Dec 25

-0.34

EPS (fwd)

Cash & equivalentsas of Dec 25: SGD 2.09M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: SGD 482.56K
Debt / equityas of Dec 25: 7.37%
Current ratioas of Dec 25: 5.17
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Dec 25: 5.17
Operating cash flowFY Dec 25: -SGD 3.69M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -SGD 4.33M
TTM revenue / diluted shareDiluted, FY Dec 25: 0.03